Asset Details
Do you wish to reserve the book?
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Do you wish to request the book?
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
2013
Overview
Patients with venous thromboembolism who had received initial anticoagulant therapy were studied in two trials of dabigatran. Dabigatran was effective in preventing recurrent venous thromboembolism and carried a lower risk of bleeding than warfarin but a higher risk than placebo.
Anticoagulant treatment with vitamin K antagonists is recommended for patients with venous thromboembolism.
1
Most patients receive at least 3 months of treatment. Long-term treatment is recommended if there are risk factors for recurrence, such as multiple thrombotic episodes.
1
In the absence of clear contraindications to anticoagulant therapy, the risk of major bleeding is approximately 1% per year with extended vitamin K antagonist therapy after venous thromboembolism.
2
The risk of major bleeding, together with the need for frequent laboratory monitoring and dose adjustments, makes long-term treatment problematic.
Dabigatran, a direct thrombin inhibitor, does not require frequent monitoring and dose adjustments. At . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Benzimidazoles - adverse effects
/ Benzimidazoles - therapeutic use
/ beta-Alanine - adverse effects
/ beta-Alanine - analogs & derivatives
/ beta-Alanine - therapeutic use
/ Biological and medical sciences
/ Bleeding
/ Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
/ Female
/ Hemorrhage - chemically induced
/ Humans
/ International Normalized Ratio
/ Male
/ Patients
/ Risk
/ Venous Thromboembolism - drug therapy
/ Venous Thromboembolism - mortality
/ Warfarin
